| Synonyms: | |
| Status: | Approved (2024) |
| Entry Type: | Small molecule |
| Molecule Category: | Free-form |
| UNII: | 7C00L34NB9 |
| InChI Key | JWHYSEDOYMYMNM-QGZVFWFLSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C21H23F3O5S |
| Molecular Weight | 444.47 |
| AlogP | 5.05 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 11.0 |
| Polar Surface Area | 64.99 |
| Molecular species | ACID |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 30.0 |
| Primary Target | |
|---|---|
| Peroxisome proliferator-activated receptor-β/δ |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 1
Nuclear hormone receptor subfamily 1 group C
Nuclear hormone receptor subfamily 1 group C member 1
|
1500 | - | - | - | - | |
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 1
Nuclear hormone receptor subfamily 1 group C
Nuclear hormone receptor subfamily 1 group C member 2
|
2-2 | - | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Liver Cirrhosis, Biliary | 3 | D008105 | ClinicalTrials |
| Hyperlipidemias | 2 | D006949 | ClinicalTrials |
| Cholangitis, Sclerosing | 2 | D015209 | ClinicalTrials |
| Non-alcoholic Fatty Liver Disease | 2 | D065626 | ClinicalTrials |
| Hyperlipoproteinemia Type II | 2 | D006938 | ClinicalTrials |
| Liver Diseases | 1 | D008107 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 851528-79-5 |
| ChEMBL | CHEMBL230158 |
| DrugBank | DB12390 |
| FDA SRS | 7C00L34NB9 |
| Guide to Pharmacology | 11137 |
| PubChem | 11236126 |
| SureChEMBL | SCHEMBL392331 |
| ZINC | ZINC000028704627 |